TransCode Therapeutics Management
Management criteria checks 4/4
TransCode Therapeutics' CEO is Tom Fitzgerald, appointed in Jul 2018, has a tenure of 5.83 years. total yearly compensation is $426.86K, comprised of 83.9% salary and 16.1% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth $22.25. The average tenure of the management team and the board of directors is 5.8 years and 5.6 years respectively.
Key information
Tom Fitzgerald
Chief executive officer
US$426.9k
Total compensation
| CEO salary percentage | 83.9% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.0006% |
| Management average tenure | 5.8yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
TransCode Therapeutics reports Q2 results
Aug 15TransCode files U.S. patent application for radiotherapy based cancer treatment
Jul 11We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely
Apr 01
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation
Dec 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$427k | US$358k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$20m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$19m |
| Dec 31 2022 | US$561k | US$371k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$318k | US$180k | -US$7m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$4m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$15k | n/a | -US$2m |
Compensation vs Market: Tom's total compensation ($USD426.86K) is below average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
CEO
Tom Fitzgerald (71 yo)
5.8yrs
Tenure
US$426,862
Compensation
Mr. Thomas A. Fitzgerald, also known as Tom, M.B.A. serves as Chief Financial Officer and Director at TransCode Therapeutics, Inc. since July 2018 (initially part-time and substantially full-time since Jan...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | 5.8yrs | US$426.86k | 0.00060% $ 22.2 | |
| Executive Chairman of the Board | 5.6yrs | US$111.54k | 0.000070% $ 2.6 | |
| Co-Founder & Chief Scientific Officer | 8.3yrs | no data | 0.0010% $ 38.2 | |
| Co-Founder | 8.3yrs | no data | 0.033% $ 1.2k | |
| Senior Vice President of Operations | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
5.8yrs
Average Tenure
64yo
Average Age
Experienced Management: RNAZ's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | 5.8yrs | US$426.86k | 0.00060% $ 22.2 | |
| Executive Chairman of the Board | 5.6yrs | US$111.54k | 0.000070% $ 2.6 | |
| Co-Founder | 8.3yrs | no data | 0.033% $ 1.2k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 3.3yrs | US$75.11k | 0% $ 0 | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 3.4yrs | US$73.11k | 0% $ 0 |
5.6yrs
Average Tenure
61yo
Average Age
Experienced Board: RNAZ's board of directors are considered experienced (5.6 years average tenure).